Screening for Visual Impairment in Children Younger Than Age 5 Years: Recommendation Statement by U.S. Preventive Services Task Force
ANNALS OF FAMILY MEDICINE  WWW.ANNFAMMED.ORG  VOL. 2, NO. 3  MAY/JUNE 2004
263
Screening for Visual Impairment in 
Children Younger Than Age 5 Years: 
Recommendation Statement 
Ann Fam Med 2004;2:263-266. DOI: 10.1370/afm.193.
This statement summarizes the U.S. Preventive Services Task Force recommendation on screening for visual impairment in children younger than age 5 years and the supporting evidence, and updates 
the 1996 recommendations contained in the Guide to Clinical Preventive Ser-
vices, Second Edition: Periodic Updates. In updating its recommendations for 
children, the USPSTF limited its review to the most common causes of 
visual impairment: amblyopia (including amblyogenic risk factors), and 
refractive error not associated with amblyopia. Explanations of the rat-
ings and of the strength of overall evidence are given in Appendix A and 
Appendix B, respectively. The complete information on which this state-
ment is based, including evidence tables and references, is available in the 
systematic evidence review1 and the update of the evidence2 on this topic, 
available through the USPSTF Web site http://www.preventiveservices. 
ahrq.gov and through the National Guideline Clearinghouse™ (http:// 
www.guideline.gov.) The recommendation statement and update of the 
evidence are also available from the Agency for Healthcare Research and 
Quality (AHRQ) Publications Clearinghouse in print through subscription 
to the Guide to Clinical Preventive Services, Third Edition: Periodic Updates. 
RECOMMENDATION
The USPSTF recommends screening to detect amblyopia, strabismus, 
and defects in visual acuity in children younger than age 5 years. 
B recommendation.
The USPSTF found no direct evidence that screening for visual impairment in children 
leads to improved visual acuity. However, the USPSTF found fair evidence that screening 
tests have reasonable accuracy in identifying strabismus, amblyopia, and refractive error 
in children with these conditions; that more intensive screening compared with usual screen-
ing leads to improved visual acuity; and that treatment of strabismus and amblyopia can 
improve visual acuity and reduce long-term amblyopia. The USPSTF found no evidence 
of harms for screening, judged the potential for harms to be small, and concluded that the 
benefi ts of screening are likely to outweigh any potential harms.
CLINICAL CONSIDERATIONS
•The most common causes of visual impairment in children are: (1) 
amblyopia and its risk factors and (2) refractive error not associated with 
amblyopia. Amblyopia refers to reduced visual acuity without a detect-
able organic lesion of the eye and is usually associated with amblyogenic 
risk factors that interfere with normal binocular vision, such as strabismus 
(ocular misalignment), anisometropia (a large difference in refractive power 
between the 2 eyes), cataract (lens opacity), and ptosis (eyelid drooping). 
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Refractive error not associated with amblyopia princi-
pally includes myopia (nearsightedness) and hyperopia 
(farsightedness); both remain correctable regardless of 
the age at detection.
• Various tests are used widely in the United States 
to identify visual defects in children, and the choice of 
tests is infl uenced by the child’s age. During the fi rst 
year of life, strabismus can be assessed by the cover 
test and the Hirschberg light refl ex test. Screening 
children younger than age 3 years for visual acuity is 
more challenging than screening older children and 
typically requires testing by specially trained personnel. 
Newer automated techniques can be used to test these 
children. Photoscreening can detect amblyogenic risk 
factors such as strabismus, signifi cant refractive error, 
and media opacities; however, photoscreening cannot 
detect amblyopia. 
• Traditional vision testing requires a coopera-
tive, verbal child and cannot be performed reliably 
until ages 3 to 4 years. In children older than age 3 
years, stereopsis (the ability of both eyes to function 
together) can be assessed with the Random Dot E test 
or Titmus Fly Stereotest; visual acuity can be assessed 
by tests such as the HOTV chart, Lea symbols, or the 
tumbling E. Some of these tests have better test charac-
teristics than others. 
• Based on their review of current evidence, the 
USPSTF was unable to determine the optimal screen-
ing tests, periodicity of screening, or technical pro-
fi ciency required of the screening clinician. Based on 
expert opinion, the American Academy of Pediatrics 
(AAP) recommends the following vision screening be 
performed at all well-child visits for children start-
ing in the newborn period to 3 years: ocular history, 
vision assessment, external inspection of the eyes and 
lids, ocular motility assessment, pupil examination, 
and red refl ex examination. For children aged 3 to 
5 years, the AAP recommends the aforementioned 
screening in addition to age-appropriate visual acuity 
measurement (using HOTV or tumbling E tests) and 
ophthalmoscopy.3
• The USPSTF found that early detection and 
treatment of amblyopia and amblyogenic risk factors 
can improve visual acuity. These treatments include 
surgery for strabismus and cataracts; use of glasses, 
contact lenses, or refractive surgery treatments to cor-
rect refractive error; and visual training, patching, or 
atropine therapy of the nonamblyopic eye to treat 
amblyopia.
• These recommendations do not address screen-
ing for other anatomic or pathologic entities, such as 
macro cornea, cataracts, retinal abnormalities, or neo-
natal neuroblastoma, nor do they address newer screen-
ing technologies currently under investigation.
DISCUSSION
Visual impairment caused by refractive error, amblyo-
pia, strabismus, and astigmatism is a common condi-
tion among young children, affecting 5% to 10% of all 
preschoolers. Amblyopia is present in 1% to 4% of pre-
school children; an estimated 5% to 7% of preschool 
children have refractive errors.2 Uncorrected amblyo-
pia may harm school performance, ability to learn, 
and later, adult self-image.4 Furthermore, uncorrected 
amblyopia may be a risk factor for future total blind-
ness. Because visual impairment in children is common 
and believed to have an early sensitive period when 
interventions lead to better outcomes, much interest 
has focused on primary care vision-screening tools for 
early detection, referral, and treatment.
The USPSTF found no direct evidence that screen-
ing for visual impairment, compared with no screening, 
leads to improved visual acuity. However, the USPSTF 
found 1 fair quality study showing that intense screen-
ing by eye professionals (compared with usual screen-
ing) decreases the prevalence of amblyopia.5 This 
recent randomized controlled trial in the United King-
dom, the Avon Longitudinal Study of Pregnancy and 
Childhood (ALSPAC) trial,5 has reported that intensive 
screening performed 6 times between ages 8 and 37 
months (using the cover test, Cardiff Cards, Kay Pic-
ture test, and HOTV letters by an eye professional) led 
to decreased prevalence of amblyopia and improved 
visual acuity compared with a 1-time visual screening 
at age 37 months (using Kays Picture test and HOTV 
letters). Any child failing a screening test was referred 
to the hospital eye service for further testing and treat-
ment. Compared with the group screened once at age 
37 months, the intensively-screened group had a signif-
icantly lower prevalence of severe amblyopia at age 7.5 
years (amblyopia B prevalence = 0.6% vs 1.8%) and a 
lower prevalence of residual amblyopia after treatment 
(7.5% vs 25%). 
The USPSTF reviewed the evidence for the accuracy 
of vision screening tests in children younger than age 5 
years. The USPSTF found no evidence evaluating the 
role of screening for family history or parental concern, 
or evaluating the accuracy of the clinical examination 
to detect visual impairments such as cataracts or stra-
bismus. One fair quality study of children aged 3 to 5 
years screened by public health nurses with annual tests, 
including Cambridge Crowding Cards, the Hirschberg 
test, and the Titmus Fly Stereotest, reported an overall 
sensitivity of 60% to 71% and a specifi city of 70% to 
80%.6 A good quality systematic review, evaluating the 
accuracy of the Snellen E test or Stycar graded balls and 
the Titmus Fly Stereotest in children aged 3 to 5 years, 
reported an estimated sensitivity of 9% to 12.5% and a 
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specifi city of 99%.7 Three poor quality studies examined 
the accuracy of the Medical Technology Incorporated 
(MTI) photoscreener™ in a population of children 
younger than age 3 years with a high prevalence of visual 
impairment. Sensitivity ranged from 37% to 88%, and 
specifi city ranged from 40% to 88%.8-10 For the Visis-
creen™ in children younger than age 3 years, overall sen-
sitivity and specifi city were 85% and 94%, respectively.11 
The USPSTF found fair quality evidence that 
early treatment of amblyogenic risk factors, includ-
ing strabismus, refractive error, and cataracts, prevents 
amblyopia.12-15 Indirect evidence for the effectiveness of 
amblyopia treatment comes from cross-sectional stud-
ies that show lower prevalence of visual impairment 
in screened populations compared with unscreened 
populations.16,17 Cohort studies show that among chil-
dren who have been diagnosed with visual impairment, 
amblyopia is unlikely to improve without therapy.18 Both 
prospective and retrospective studies report that between 
approximately 40% and 95% of persons with amblyopia 
have improved visual acuity after treatment.19-31 Two fair 
quality studies of treatment for amblyopia have found 
that successful outcomes depend on earlier treatment.32,33 
In these studies, treatment effi cacy steadily decreased 
after age 3 years; by age 12 years, treatment was inef-
fective. However, there is fair evidence to suggest that 
a modest delay in treatment does not harm outcomes.34 
Since the USPSTF found no studies that followed 
patients into adulthood, the long-term effectiveness of 
the interventions for amblyopia is unclear.
The USPSTF found no studies detailing permanent 
harms resulting from screening or data regarding the 
harms of false-positive screening. However, potential 
harms of screening may include “labeling” and the costs 
associated with the further evaluation of children with 
false-positive screening results. Potential harms of inter-
ventions include disruption of normal eye development 
and temporary loss of visual acuity of the nonamblyopic 
eye, which resolves weeks after completion of therapy.35
There is limited research regarding the performance 
of vision screening tests in the primary care setting, 
although there are studies currently underway com-
paring various screening methods.36-38 Current stud-
ies reviewed by the USPSTF, including the ALSPAC 
study,5 support the effectiveness of intensive screening; 
however, it is not clear whether the magnitude of ben-
efi t observed in the United Kingdom study is gener-
alizable to the United States population, to children 
younger than age 3 years, or to services provided by 
primary care clinicians. It would be helpful if similar 
studies comparing early, intensive screening to usual 
visual screening were performed in children younger 
than age 5 years using screening tests commonly per-
formed in the United States by primary care clinicians.
RECOMMENDATIONS OF OTHER GROUPS
The recommendation of the American Acad-
emy of Family Physicians can be accessed at http://
www.aafp.org/x7661.xml. The joint recommendation of 
the American Academy of Pediatrics, American Asso-
ciation for Pediatric Ophthalmology and Strabismus, 
and the American Academy of Ophthalmology, can be 
accessed at http://aap.org/policy/s0208.html. 
The clinical practice guideline of the American Opto-
metric Association can be accessed at http://www.aoa.org/
eweb/Documents/CPG-2.pdf. The recommendation of 
the Canadian Task Force on the Periodic Health Exami-
nation can be accessed at http://www.ctfphc.org. 
APPENDIX A
U.S. Preventive Services Task Force Recommendations and Ratings
The Task Force grades its recommendations according to one of 5 
classifi cations (A, B, C, D, I) refl ecting the strength of evidence and 
magnitude of net benefi t (benefi ts minus harms):
A. The USPSTF strongly recommends that clinicians provide [the ser-
vice] to eligible patients. The USPSTF found good evidence that [the 
service] improves important health outcomes and concludes that 
benefi ts substantially outweigh harms.
B. The USPSTF recommends that clinicians provide [the service] to 
eligible patients. The USPSTF found at least fair evidence that [the 
service] improves important health outcomes and concludes that 
benefi ts outweigh harms.
C. The USPSTF makes no recommendation for or against routine 
provision of [the service]. The USPSTF found at least fair evidence 
that [the service] can improve health outcomes but concludes that 
the balance of benefi ts and harms is too close to justify a general 
recommendation.
D. The USPSTF recommends against routinely providing [the service] 
to asymptomatic patients. The USPSTF found at least fair evidence 
that [the service] is ineffective or that harms outweigh benefi ts.
I. The USPSTF concludes that the evidence is insuffi cient to recom-
mend for or against routinely providing [the service]. Evidence that 
[the service] is effective is lacking, of poor quality, or confl icting, 
and the balance of benefi ts and harms cannot be determined.
APPENDIX B
U.S. Preventive Services Task Force Strength of Overall Evidence
The USPSTF grades the quality of the overall evidence for a service 
on a 3-point scale (good, fair, poor):
Good
Evidence includes consistent results from well-designed, well-con-
ducted studies in representative populations that directly assess 
effects on health outcomes.
Fair
Evidence is suffi cient to determine effects on health outcomes, but 
the strength of the evidence is limited by the number, quality, or 
consistency of the individual studies, generalizability to routine 
practice, or indirect nature of the evidence on health outcomes.
Poor
Evidence is insuffi cient to assess the effects on health outcomes 
because of limited number or power of studies, important fl aws in 
their design or conduct, gaps in the chain of evidence, or lack of 
information on important health outcomes.
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To read or post commentaries in response to this article, see it 
online at http://www.annfammed.org/cgi/content/full/2/3/263. 
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Disclaimer: Recommendations made by the USPSTF are independent of 
the U.S. Government. They should not be construed as an offi cial position 
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